AU2440001A - Tethered ligands and methods of use - Google Patents

Tethered ligands and methods of use

Info

Publication number
AU2440001A
AU2440001A AU24400/01A AU2440001A AU2440001A AU 2440001 A AU2440001 A AU 2440001A AU 24400/01 A AU24400/01 A AU 24400/01A AU 2440001 A AU2440001 A AU 2440001A AU 2440001 A AU2440001 A AU 2440001A
Authority
AU
Australia
Prior art keywords
methods
domain
ligand
tethered ligands
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24400/01A
Other languages
English (en)
Inventor
Zhenhua Miao
Thomas J. Schall
Dale Talbot
Zheng Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemocentryx Inc
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of AU2440001A publication Critical patent/AU2440001A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU24400/01A 1999-12-20 2000-12-18 Tethered ligands and methods of use Abandoned AU2440001A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17297999P 1999-12-20 1999-12-20
US60172979 1999-12-20
US18662600P 2000-03-03 2000-03-03
US60186626 2000-03-03
US09/721,908 US6699677B1 (en) 1999-12-20 2000-11-24 Tethered ligands and methods of use
US09721908 2000-11-24
PCT/US2000/034503 WO2001046698A2 (en) 1999-12-20 2000-12-18 Tethered ligands and methods of use

Publications (1)

Publication Number Publication Date
AU2440001A true AU2440001A (en) 2001-07-03

Family

ID=27390216

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24400/01A Abandoned AU2440001A (en) 1999-12-20 2000-12-18 Tethered ligands and methods of use

Country Status (9)

Country Link
US (1) US6699677B1 (enExample)
EP (1) EP1247103B1 (enExample)
JP (1) JP4777570B2 (enExample)
AT (1) ATE405838T1 (enExample)
AU (1) AU2440001A (enExample)
CA (1) CA2390690C (enExample)
DE (1) DE60040019D1 (enExample)
ES (1) ES2311485T3 (enExample)
WO (1) WO2001046698A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998239B1 (en) * 1999-10-12 2006-02-14 Chemocentryx, Inc. Method for identifying a modulator of the binding of CCX CKR polypeptide to a chemokine
USRE39849E1 (en) 1999-10-12 2007-09-18 Chemocentryx, Inc. Methods for identifying modulators of CCX CKR activity
US6780602B2 (en) * 2001-11-01 2004-08-24 Microbiosystems, Limited Partnership Taxonomic identification of pathogenic microorganisms and their toxic proteins
US7413866B2 (en) * 2001-11-30 2008-08-19 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7504364B2 (en) 2002-03-01 2009-03-17 Receptors Llc Methods of making arrays and artificial receptors
US20060160076A1 (en) * 2002-06-10 2006-07-20 Meatabolex, Inc. Methods of treating and diagnosing diabetes with cx3cr1 modulators
US7469076B2 (en) 2003-09-03 2008-12-23 Receptors Llc Sensors employing combinatorial artificial receptors
US20040115634A1 (en) 2002-12-11 2004-06-17 Isis Pharmaceuticals, Inc. Modulation of stat 6 expression
US7981694B2 (en) * 2003-01-28 2011-07-19 The Regents Of The University Of California Solid phase isolation of proteins, nucleic acids and other macromolecules
GB0306428D0 (en) * 2003-03-20 2003-04-23 Oxagen Ltd Receptor proteins
EP1613737A4 (en) 2003-03-28 2008-12-03 Receptors Llc ARTIFICIAL RECEPTORS COMPRISING REVERSIBLE IMMOBILIZED CONSTRUCTION BLOCKS AND METHODS
EP1656092B1 (en) * 2003-08-12 2008-07-23 Philips Intellectual Property & Standards GmbH Closure device for a container
DK2211183T3 (da) * 2003-11-19 2013-05-13 Satoris Inc Fremgangsmåde til diagnosticering og overvågning af Alzheimer's sygdom
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
US7884052B2 (en) 2004-09-03 2011-02-08 Receptors Llc Combinatorial artificial receptors including tether building blocks on scaffolds
EP1789792A2 (en) 2004-09-11 2007-05-30 Receptors LLC Combinatorial artificial receptors including peptide building blocks
US7585968B2 (en) 2005-03-28 2009-09-08 Isis Pharmaceuticals, Inc. Compositions and their uses directed to thymus and activation-regulated chemokine (TARC)
US20060258610A1 (en) 2005-05-12 2006-11-16 Isis Pharmaceuticals, Inc. Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness
WO2007005715A2 (en) * 2005-07-01 2007-01-11 Inhibtex, Inc. Staphylococcal antibodies which cross-react with fungal antigens
CA2673085C (en) 2006-12-12 2013-10-15 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
WO2009124295A2 (en) * 2008-04-04 2009-10-08 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
US20110202284A1 (en) * 2010-02-10 2011-08-18 Mcreynolds Cristopher Novel groups of biomarkers for diagnosing alzheimer's disease
US9163094B2 (en) 2011-09-27 2015-10-20 Massachusetts Institute Of Technology Light-activated fusion proteins and uses therefor
US9718887B2 (en) 2012-09-06 2017-08-01 Adelaide Research & Innovation Pty Ltd Methods and products for preventing and/or treating metastatic cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08507602A (ja) 1993-02-19 1996-08-13 アリス・ファーマスーティカル・コーポレイション リガンドを構成しかつ提示するための薄膜ｈｐｍｐマトリックス系および方法
JPH07147987A (ja) 1993-05-28 1995-06-13 Wisconsin Alumni Res Found ユビキチン接合性酵素（ｅ２）融合タンパク質
US5763199A (en) 1994-09-29 1998-06-09 Mount Sinai School Of Medicine Of The City University Of New York Platelet blockade assay
US5817527A (en) 1995-11-06 1998-10-06 Chiron Diagnostics Corporation Conjugation of ligand to immobilized protein in organic solvent
EP0876487B1 (en) 1996-01-24 2008-03-12 Schering Corporation Mammalian cx3c chemokine genes
WO1998049557A1 (en) 1997-04-28 1998-11-05 B-E Safe, Inc. Taxonomic identification of microorganisms, proteins and peptides involved in vertebrate disease states

Also Published As

Publication number Publication date
JP4777570B2 (ja) 2011-09-21
ATE405838T1 (de) 2008-09-15
CA2390690C (en) 2010-08-10
JP2003518138A (ja) 2003-06-03
ES2311485T3 (es) 2009-02-16
CA2390690A1 (en) 2001-06-28
US6699677B1 (en) 2004-03-02
EP1247103B1 (en) 2008-08-20
EP1247103A2 (en) 2002-10-09
DE60040019D1 (de) 2008-10-02
WO2001046698A3 (en) 2002-02-21
WO2001046698A2 (en) 2001-06-28

Similar Documents

Publication Publication Date Title
AU2440001A (en) Tethered ligands and methods of use
AU3227400A (en) Flow cell, analyte measurement apparatus and methods related thereto
AU1671300A (en) Cancer detection method and reagents
WO2002043758A3 (en) Uses of mammalian genes and related reagents
AU3433601A (en) Multiple analyte assay device with sample integrity monitoring system
AU5437999A (en) Method of electrochemical analysis of an analyte
WO2001042786A3 (en) System for cell based screening : cell spreading
AU4694499A (en) Trace level detection of analytes using artificial olfactometry
EP1854808A3 (en) Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
WO2000023614A8 (en) Method for monitoring proteasome inhibitor drug action
AU6834700A (en) Device and method for determining multiple analytes
AU2001250412A1 (en) Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction
AU4005700A (en) Noninvasive transdermal systems and methods for detecting an analyte in a biological fluid
AU3260299A (en) Immunoassays involving surface enhanced raman scattering
AU9066998A (en) Use of check surfaces for identifying disturbing samples in a detection procedure
WO2004057341A3 (en) Cvd assay
AU7636300A (en) Non-separation heterogenous assay for biological substances
TW200504365A (en) Adhered membranes retaining porosity and biological activity
AU1919201A (en) Mammalian receptor proteins; related reagents and methods
AU4169700A (en) Simultaneous analysis of an analyte and an interfering substance using flow cytometry
WO2001042503A3 (en) Apparatus and methods for drug screening based on nucleic acid analysis
FR2780062B1 (fr) Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
EP1258018A4 (en) REAGENTS, METHODS AND KITS FOR PROTEIN DETECTION i BACILLUS THURINGIENSIS / i
WO2004010143A3 (en) Electrochemical lateral flow and flow-through devices
WO2004037160A3 (en) In vitro test for studying compound predicting pharmacologic and/or pharmacokinetic and/or pharmacodynamic parameters of a compound

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase